The Epidemiology of Endometrial and Ovarian Cancer by Cramer, Daniel William
The Epidemiology of
Endometrial and Ovarian Cancer
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Cramer, Daniel W. 2012. “The Epidemiology of Endometrial and
Ovarian Cancer.” Hematology/Oncology Clinics of North America 26
(1) (February): 1–12. doi:10.1016/j.hoc.2011.10.009.
Published Version doi:10.1016/j.hoc.2011.10.009
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27332628
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
The Epidemiology of Endometrial and Ovarian Cancer
Daniel W. Cramer, M.D., Sc.D.
Brigham and Women’s Hospital, Department of Obstetrics and Gynecology
Introduction
The epidemiology of ovarian cancer and endometrial cancer is closely entwined. Age
specific incidence curves and the international rates for both sites parallel each other, and
histologic subtypes of cancer arising from the endometrium mirror types found in the ovary.
Most of the personal factors that increase or decrease risk for one of these cancers act in the
same direction for the other. For these reasons, we will consider the epidemiology of ovarian
and endometrial cancer together in this chapter with the goal of providing a more unified
perspective. We will not address the epidemiology of cervical cancer in this chapter. This is
not for lack of importance. Worldwide cervical cancer is a greater source of morbidity and
mortality than endometrial and ovarian cancer combined (Table 1). However, there are
many fewer epidemiologic uncertainties related to cervical cancer; and means of prevention
and early detection are in hand, if not yet fully implemented where they are most needed.
Tumor heterogeneity as it may affect epidemiologic associations
Before discussing the epidemiology of endometrial and ovarian cancer, it must be pointed
out that neither of these cancers is homogeneous from a histopathologic standpoint. Cancer
registries often include endometrial cancer under the broader category “cancers of the
uterine corpus,” which includes sarcomas that arise from the endometrial stroma or from the
smooth muscle of the uterus. Adenocarcinomas comprise the vast majority of cancers of the
“uterine corpus” and most epidemiologic studies are restricted to these. In turn, endometrial
adenocarcinomas may be further subdivided with endometrioid (or Type I) cancers
accounting for majority, about 85%, and the remainder designated Type II and including
adenosquamous, serous papillary, clear cell, and undifferentiated types similar to those
found in the ovary [1, 2].
There is an even greater degree of heterogeneity for ovarian cancer. Ovarian malignancies
may arise from germ cell, stromal, or epithelial compartments. Counting benign neoplasms,
about 25% of all ovarian tumors are of germ cell origin. Most common is the mature
teratoma (dermoid) which accounts for nearly 1/3 of all benign ovarian neoplasms, but only
2-3% of germ cell tumors are malignant [3]. Ovarian stromal tumors account for 6% of all
benign and malignant ovarian tumors with the most common being the granulosa cell tumor
which accounts for approximately 10% of malignant ovarian cancers. The most common
types of malignant ovarian cancers are epithelial and parallel the same types arising in the
endometrium. Four major histologic subtypes of epithelial ovarian cancer have been
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described, each resembling different types of epithelia found in the female reproductive tract
[4]. Features associated with fallopian tube, endocervical or endometrial epithelia are
observed in serous, mucinous and endometrioid forms of ovarian cancer, respectively. Clear
cell tumors are the fourth major histological subtype and are identified by clear, peg-like
cells that resemble the lining of the endometrial glands during pregnancy. The majority of
malignant ovarian tumors fall into the invasive serous category followed by endometrioid,
clear cell, and mucinous types.
A distinction made for ovarian cancer that does not have an exact parallel in endometrial
cancer is the designation of borderline or low malignant potential (LMP) ovarian tumor
types that may spread beyond the ovary yet generally have an indolent course and account
for about 17-18% of ovarian cancers. The Surveillance, Epidemiology, and End Result
(SEER) agency at the National Cancer Institute decided to no longer count LMP ovarian
tumors as cancers after Jan 1, 2004. As a consequence, about a 20% “decrease” in the
incidence of ovarian cancer and a 5% decrease in mortality occurred between 2004 and
2006.
In conclusion then, epidemiologic patterns observed for endometrial cancer are most likely
to pertain to the Type I cancers while that for ovarian cancer to invasive serous. However,
because of the greater heterogeneity of ovarian cancer, the mix of cases from study to study
may influence epidemiologic associations reported for ovarian cancer especially if LMP
tumors are included.
Age and Geographic Distribution
In the U.S., endometrial cancer is the most common gynecologic cancer accounting for
40,100 new cases and 7,470 deaths [5]. Ovarian cancer accounts for fewer cases (21,650)
but more deaths (15,520) [5]. Ovarian cancer is the leading cause of death from a
gynecologic cancer and fifth leading cause of cancer deaths overall in the U.S. Endometrial
and ovarian cancer share similar patterns of distribution by age and geography. Both cancers
rise sharply in occurrence during the perimenopausal years and peak well after the
menopause (Fig 1). Endometrial cancer rates drop after age 70, but ovarian cancer rates
continue to rise into a woman’s eighties. It should be appreciated that the age specific rates
for ovarian cancer calculated by SEER are based on the entire US population of females
including those who have had hysterectomy or hysterectomy and oophorectomy [6]. Except
when the operation was done for endometrial or ovarian cancer, women who have had such
operations are virtually at no future risk for these cancers. Because of this, it is estimated
that rates overall are about 33% higher for endometrial cancer and about 15% higher for
ovarian cancer, although the exact percentages differ somewhat by age [7]. The
corresponding dashed lines in Figure 1 illustrate the predicted higher incidence rates for
women who still have their uterus or ovaries. Using these corrected incidence rates, the
lifetime risk for endometrial cancer is about 5.7% if women with hysterectomy for benign
conditions are excluded and 2.5% for ovarian cancer if women with hysterectomy and
oophorectomy are excluded.
Worldwide, higher rates of endometrial and ovarian cancer are observed in industrialized
and Northern European populations and lower rates in third world countries [8] (Table 1).
There is a positive correlation between endometrial cancer occurrence and ovarian cancer
occurrence that is significant (Pearson correlation = 0.76, p<0.001). For comparison, the
rates of cervical cancer are also shown and are inversely correlated with both endometrial
cancer (Pearson correlation = -0.64, p<0.001) and ovarian cancer (Pearson correlation =
-0.57, p=0.003).
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Risk Factors
In this section we will consider personal risk factors for endometrial and ovarian cancers
organized under the following headings: menstrual and reproductive events, medical history,
and habits and environment (Table 2). Genetic risk for these cancers is treated in a separate
chapter.
Menstrual and reproductive events
Personal risk factors for endometrial and ovarian cancer often operate in the same direction
and many of these relate to menstrual and reproductive events. Factors that decrease risk for
both endometrial and ovarian cancer include a late age at menarche [9, 10], early age at first
birth [9-12] as well as last pregnancy at a later age [12-14], a greater number of children
[9-14], and longer period of breastfeeding children [15-19]. With the exception of estrogen
dominant sequential oral contraceptives, which case reports linked to endometrial cancer
[20], longer use of combination oral contraceptives reduces the risk for both endometrial and
ovarian cancer [21-24]. Short or irregular cycles [9, 10] and a late age at menopause are
associated with increased risk for both endometrial cancer and ovarian cancers [13, 25].
These above events can be fit into a composite variable that estimates years of ovulation or,
when average cycle length is included, number of ovulatory cycles. Increasing ovulatory
cycles clearly correlates with increased risk for ovarian cancer [26, 27]. Though less well
studied, ovulatory cycles also appears to correlate directly with endometrial cancer risk [28].
Despite the appeal of an ovulatory cycles model for consolidating many of the reproductive
factors, it is also true that other contraceptive methods not associated with cessation of
ovulation may also affect endometrial and ovarian cancer. IUD use, even hormonally inert
types, decreases the risk for endometrial cancer [29, 30] and studies suggests IUD use (at
least short term) may also decrease the risk for ovarian cancer [31, 32]. Similarly, tubal
ligation is a strong protective risk factor for ovarian cancer that may also decrease the risk
for endometrial cancer [33-36]. Finally, another risk factor for endometrial and ovarian
cancer is menopausal hormone use, with higher risk largely confined to users of estrogen
only forms unopposed by a progestin [37-42].
Medical history
High body mass index (BMI) is a well-established risk factor for Type I endometrial cancer
and has been linked to elevated levels of estrogen, particularly in post-menopausal women
where adipose tissue is the main site of estrogen production from androgen precursors
[43-45]. High BMI also appears to be associated with increased ovarian cancer risk possibly
through similar hormonal mechanisms, although the risk is not as strong as that for
endometrial cancer [46-48]. Polycystic ovarian syndrome, a condition characterized by
ovarian hyperandrogenism, chronic anovulation and progesterone deficiency, has also been
associated with increased risk for both ovarian and endometrial cancer [49-51]. A history of
bone fracture may decrease risk for endometrial and possibly ovarian cancer [32, 52, 53] and
may reflect long-term hypoestrogenic status. For reasons not entirely clear Systemic Lupus
Erythematosus (SLE) may decrease risk for endometrial and ovarian cancer [54].
Habits and environmental factors
Current smoking is associated with a reduced risk for endometrial cancer, particularly in
postmenopausal women, possibly due to the anti-estrogenic effects of smoking such as
reduced body weight, lower age at menopause and differences in estrogen metabolism [55].
Current smoking has also been associated with decreased risk of clear cell ovarian tumors,
however no association was observed with serous and endometrioid tumors; and smoking
doubled the risk of mucinous ovarian cancers [56]. Talc use is another factor found to
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consistently increase the risk for ovarian cancer [57] and recently reported to increase the
risk for endometrial cancer as well [58]—raising intriguing questions related to the
pathogenic mechanism underlying these associations. Increased exercise and physical
activity decreases the risk for endometrial [59-61] and possibly ovarian cancer [62].
In summary, this brief review of epidemiologic risk factors for endometrial and ovarian
cancers reveals a surprising number of similarities which suggests that there are also shared
mechanisms in their pathogenesis.
Mechanisms
An ultimate goal of epidemiology is to clarify the biologic basis for observations made
about a disease leading to a better understanding of its pathogenesis and strategies for its
control. For endometrial cancer, it has been accepted for many years that its epidemiology is
largely explained by conditions which lead to an excess of estrogen relative to progesterone.
A “natural experiment” testing this explanation was the increase in endometrial cancer
incidence which followed the increased use of unopposed estrogen to treat menopausal
symptoms during the 1970’s [63]. The strong link between obesity and endometrial cancer is
likely explained by the fact that fat possesses aromatase capable of converting
androstenedione into estrone, a biologically active estrogen [43]. The fact that endometrial
cancer increases dramatically during the perimenopause when anovulatory cycles become
more common provides further physiologic support. The protective effect of smoking on
endometrial cancer risk may relate to possible anti-estrogen effects of smoking. However, it
is more difficult to explain how estrogen excess fits with the association between
endometrial cancer and ovulatory cycles and even less clear how IUD use, tubal ligation, or
talc use fits with estrogen excess.
The most popular explanation for ovarian cancer risk factors is the “incessant ovulation”
theory [64]; and this may be of interest to the connection between ovulatory cycles and
endometrial cancer. For ovarian cancer, it has been proposed that the monthly disruption and
repair of the surface epithelium of the ovary may lead to genetic damage due to the
accumulation of mutations of the tumor suppressor, p53, in the ovarian and possible
fallopian tube epithelium [65, 66]; but this mechanism would not explain the association
with endometrial cancer. One possibility is that “incessant ovulation” largely equates with
“incessant menstruation” involving repeated disruption and re-growth of the uterine lining.
A greater number of cycles of endometrial regeneration may increase the likelihood of
random genetic mutations because DNA replication errors occur during cell division, and
thus are more likely to occur in tissues undergoing many cell divisions. Estimates of the rate
of sporadic mutagenesis in human cells, on the order of 10-7 mutations per gene per cell
division [67] suggest that the number of cells with “first hits” on a multistep carcinogenesis
pathway [68] may number in the hundreds for every gram (109 cells/gram) of proliferative
tissue. It is no surprise, then, to find that sporadic mutations of another tumor suppressor
gene, PTEN, are observed in almost half (43%) of histologically normal endometria of
naturally cycling premenopausal women [69]. Thus accumulation of mutations in p53 or
PTEN associated with reproductive tissue turnover could be the common explanation that
links ovulatory cycles with both endometrial and ovarian cancer risk.
Another popular theory offered to explain ovarian cancer risk factors is inflammation
associated with ovulation, talc use, or endometriosis [70]. This theory could explain why
tubal ligation would be protective by blocking talc or menstrual debris from reaching the
ovaries. However this theory would not explain why tubal ligation may also protect against
endometrial cancer or why IUD use protects against endometrial and possibly ovarian
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cancer as well. No existing theory readily explains an inverse association between mumps
parotitis and ovarian cancer reported in early studies [71, 72].
Recently, we proposed a new paradigm [32] for ovarian cancer that may also explain aspects
of endometrial cancer risk as well. Risk factors for ovarian cancer may be determined by
factors affecting the immune system—acute events in younger life which primed the
immune system to recognize and eliminate ovarian cancer precursors and/or chronic events
that led to persistent antigen challenge and immune tolerance of an emerging cancer [32].
The acute events include mumps, mastitis, tubal ligation, and others that affect tissues which
express surface glycoproteins known as mucins (MUC), especially MUC1, including
salivary glands, breast ducts, fallopian tubes, and others. Normally, MUC1 is expressed in
low levels in a highly-glycosylated form, whereas, in cancer, MUC1 is expressed at high
levels in a less-glycosylated form where backbone peptides are exposed to the immune
system and evoke anti-MUC1 antibodies described in a variety of cancers [73] as well as
certain inflammatory conditions like ulcerative colitis [74]. The “inflammatory” form of
MUC1 is similar to the tumor-like form of MUC1 and hence might prime the immune
system to recognize nascent cancer cells or precursor lesions which express this form of
MUC1 [73]. The number and diversity of these acute events, their age at occurrence, and
whether their benefits are negated by chronic inflammatory events determine whether
effective, long-term immune surveillance is created. The chronic events like incessant
ovulation, talc use, and endometriosis, also affect tissues that express MUC1 and may also
lead to expression of an “inflammatory” form of mucins. However, because the events are
chronic, we hypothesize they lead to immune-tolerance of an emerging cancer.
Supporting our theory are findings that events like tubal ligation and mastitis, which raised
anti-MUC1 antibody levels in controls from the New England Case Control study, are
associated with lower risk for ovarian cancer; and, conversely, factors that decreased anti-
MUC1 antibody levels (e.g. talc use and estimated ovulatory cycles) increased the risk for
ovarian cancer [32, 75]. Prospective data from the Nurses Health Studies (NHS) confirmed
the importance of tubal ligation raising antibodies and ovulatory cycles lowering them [76].
Importantly, the NHS study found that the presence of anti-MUC1 antibodies in bloods
drawn at least 3 years prior to a clinical diagnosis of ovarian cancer predicted lower risk for
ovarian cancer in women less than 64 years of age at blood draw. In women >64 at blood
draw a protective association was not apparent for two reasons. First, anti-MUC1 antibody
levels in controls declined after age 64 likely due to aging of the immune system (immuno-
senescence)—a well described phenomenon in vaccine literature [77]. Secondly it would
appear that women with the lowest anti-MUC1 antibody levels may develop ovarian cancer
soonest leaving older women destined to develop ovarian cancer with relatively higher (but
ineffective) levels of antibodies. As a final piece of evidence, we found that individuals
going through a mumps infection have significantly higher anti-MUC1 antibody levels than
blood bank or community controls providing evidence that mumps may have exerted its
protective effect though MUC1 immunity [78].
In summary, reproductive tissue turnover as well as mucin-related immunity both offer more
comprehensive explanations for endometrial and ovarian cancer risk factors than the
separate models currently proposed. As we recently argued in a paper addressing immune
surveillance in cancer [79], an appeal of an immune-based model is that it is capable of
explaining risk factors for many types of cancer based upon possible deleterious effects of
aging, obesity, smoking, lack of childhood illness, and even talc use on the immune system.
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Strategies for prevention
Epidemiologists are primarily concerned with ways to prevent disease from occurring in the
first place or detecting the disease at an earlier stage so that it can be more successfully
treated. Because many of the risk factors for endometrial and ovarian cancer are similar,
suggestions for preventing endometrial cancer may pertain to ovarian cancer as well.
Maintenance of a healthy weight and a lifetime commitment to exercise would be beneficial
for both ovarian and endometrial cancer. Breastfeeding after pregnancy and use of birth
control pills are two equally important recommendations to reduce risk. Avoiding talc in
pelvic hygiene is good advice to women to lower ovarian cancer risk that may also help
lower endometrial cancer risk as well. Many women come to hysterectomy for benign
conditions and they are obviously no longer at risk for endometrial cancer. Careful selection
of women for incidental oophorectomy would prevent them from developing ovarian cancer
as well. We have recently describe a risk scoring scheme to help physicians and patients
decide who might be advised to have oophorectomy [80].
There are currently no recommendations regarding general population screening for either
endometrial or ovarian cancer, although screening may be warranted in groups at high risk
for ovarian or endometrial cancer. Should more sensitive and specific screening tests
become available, the sharply rising incidence of these cancers during the 50 to 65 age range
suggests this would be a good age group to target screening efforts.
Conclusion
This review has highlighted similarities in the epidemiology of endometrial and ovarian
cancer that includes highly correlated incidence rates and similar risk factor profiles. Factors
that decrease risk for both cancers include a late menarche, early age at first birth, giving
birth and breastfeeding, and use of oral contraceptives. Short or irregular cycles and late
menopause is associated with increased risk for both. Other risk factors that appear to
operate in a similar direction include decreased risk associated with IUD use or a tubal
ligation and increased risk associated with obesity, lack of exercise, and use of talc powders
in genital hygiene. Estrogen excess is proposed as the underlying mechanism for most
endometrial cancer while incessant ovulation has been suggested as the explanation for
ovarian cancer. However, an increased number of estimated ovulatory cycles correlates
directly with both endometrial and ovarian cancer risk suggesting that reproductive tissue
turnover with an accumulation of PTEN or p53 mutation represents a possible common
mechanism. An immune-based explanation involving mucin proteins represents another
common mechanism that could explain additional risk factors. Maintenance of ideal weight,
breastfeeding children, use of oral contraceptives, and avoidance of talc powders in genital
hygiene are measures that could lower risk for both types of cancer. Careful selection of
women for prophylactic oophorectomy for women who are coming to hysterectomy for
benign disease is an additional measure to consider for ovarian cancer.
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Figure 1.
Age-Specific Incidence Rates of Endometrial and Ovarian Cancers1.
1Age-Specific Cancer Incidence Rates are per 100,000 and are age-adjusted. Rates include
all races and pertain to invasive cancers only. [6]
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